Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Liver Cancer

Liver Cancer

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Liver Cancer

184 trials tracked for Liver Cancer: 21 in phase 3 or 4 and 12 with published results. The most-cited published study has 258 citations.

184Trials tracked
21Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 3 Phase 3 18 Phase 2 113 Phase 1 13 Other / NA 37
  1. Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed · 258 cited
  2. Phase 3 A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) Completed · 252 cited
  3. Phase 3 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Completed · 153 cited
  4. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 130 cited
  5. Phase 3 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed · 120 cited
  6. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
Show 44 more trials
  1. Phase 3 Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas Completed · 87 cited
  2. Phase 3 Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection Completed · 82 cited
  3. Phase 3 Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Completed · 78 cited
  4. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Completed · 50 cited
  5. Phase 3 Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer Completed · 22 cited
  6. Phase 3 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival Completed · 8 cited
  7. Phase 4 SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA Completed
  8. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  9. Phase 3 SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization Completed
  10. Phase 3 SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization Completed
  11. Phase 3 Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC Completed
  12. Phase 3 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Completed
  13. Phase 3 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer Completed
  14. Phase 3 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma Completed
  15. Phase 3 Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer Completed
  16. Phase 2 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed
  17. Phase 2 A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Completed
  18. Phase 2 Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Completed
  19. Phase 2 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Completed
  20. Phase 2 Study of BGB-A317 in Participants With Previously Treated Unresectable HCC Completed
  21. Phase 2 Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Completed
  22. Phase 2 IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Completed
  23. Phase 2 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed
  24. Phase 2 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma Completed
  25. Phase 2 Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets Completed
  26. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  27. Phase 2 Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed
  28. Phase 2 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
  29. Phase 2 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Completed
  30. Phase 2 Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Completed
  31. Phase 2 Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Completed
  32. Phase 2 Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Completed
  33. Phase 2 Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Completed
  34. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
  35. Phase 2 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Completed
  36. Phase 2 Survivorship Promotion In Reducing IGF-1 Trial Completed
  37. Phase 2 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver Completed
  38. Phase 2 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed
  39. Phase 2 Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy Completed
  40. Phase 2 Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Completed
  41. Phase 2 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Completed
  42. Phase 2 Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery Completed
  43. Phase 2 Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed
  44. Phase 2 IMC-A12 in Treating Patients With Advanced Liver Cancer Completed

Showing the 50 most-cited and recently-updated of 184 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Oncology Meta-analysis
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
Frontiers Jun 11, 2026
Narrative review of lung, breast, liver, and kidney cancer evidence
Urology Meta-analysis
Narrative review of lung, breast, liver, and kidney cancer evidence New Cancer Tests Could Spot Tumors Years Earlier Than Before
This narrative review synthesizes published English-language evidence on lung, breast, liver, and kidney cancers. The authors note the scope…
A new wave of cancer biomarker tests can spot lung, breast, liver, and kidney tumors years earlier, opening the door to faster treatment and…
Frontiers May 9, 2026
Review of combination strategies for digestive system tumors including gastric and colorectal cancer
Allergy & Immunology Sys. Review
Review of combination strategies for digestive system tumors including gastric and colorectal cancer Unlocking New Ways to Beat Drug Resistance in Digestive Cancers
This review examines theoretical approaches to enhance efficacy in patients with digestive system tumors, including gastric, colorectal, and…
Researchers are finding better ways to combine treatments so drugs keep working longer.
Frontiers Apr 23, 2026
Laparoscopic hemihepatectomy shows higher costs but better QALYs than open approach in European trial
Gastroenterology RCT
Laparoscopic hemihepatectomy shows higher costs but better QALYs than open approach in European trial Laparoscopic surgery costs more upfront but may offer better value for some liver patients
A phase 3 randomized controlled trial of 332 patients undergoing hemihepatectomy at 16 European centers found laparoscopic surgery had highe…
Laparoscopic liver surgery costs more upfront but delivers better long-term value and quality of life for patients.
Apr 10, 2026